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Rett syndrome (RTT) is a severe X-linked neurodevelopmental
disorder mainly affecting females and is associated with
mutations in MECP2, the gene encoding methyl CpG-binding pro-
tein 2. Mouse models suggest that recombinant human insulin-
like growth factor 1 (IGF-1) (rhIGF1) (mecasermin) may improve
many clinical features. We evaluated the safety, tolerability, and
pharmacokinetic profiles of IGF-1 in 12 girls with MECP2 muta-
tions (9 with RTT). In addition, we performed a preliminary as-
sessment of efficacy using automated cardiorespiratory measures,
EEG, a set of RTT-oriented clinical assessments, and two standard-
ized behavioral questionnaires. This phase 1 trial included a 4-wk
multiple ascending dose (MAD) (40–120 μg/kg twice daily) period
and a 20-wk open-label extension (OLE) at the maximum dose.
Twelve subjects completed the MAD and 10 the entire study, with-
out evidence of hypoglycemia or serious adverse events. Mecasermin
reached the CNS compartment as evidenced by the increase in
cerebrospinal fluid IGF-1 levels at the end of the MAD. The drug
followed nonlinear kinetics, with greater distribution in the periph-
eral compartment. Cardiorespiratory measures showed that apnea
improved during the OLE. Some neurobehavioral parameters, specif-
ically measures of anxiety and mood also improved during the OLE.
These improvements in mood and anxiety scores were supported by
reversal of right frontal alpha band asymmetry on EEG, an index of
anxiety and depression. Our data indicate that IGF-1 is safe and well
tolerated in girls with RTT and, as demonstrated in preclinical studies,
ameliorates certain breathing and behavioral abnormalities.
R
ett syndrome (RTT), the second most common cause of
severe intellectual disability in females, is associated in the
majority of cases with mutations in MECP2, a gene on Xq28 that
encodes the transcriptional regulator methyl CpG-binding pro-
tein 2 (1). The disorder is characterized by apparent normal early
development followed by subsequent psychomotor regression
in early childhood, affecting predominantly language and pur-
poseful hand skills (1–3). Gait impairment and stereotypic hand
movements are the other two main diagnostic criteria. Other
common features, some of which are considered supportive di-
agnostic criteria, include growth retardation, breathing disturbances,
seizures, and behavioral abnormalities (1). Current RTT treatments
are focused on managing neurological symptoms (e.g., seizures,
anxiety) and medical comorbidities (e.g., constipation, scoliosis), but
have had limited success (4).
Initial drug trials for RTT, including two randomized placebo-
controlled trials, were based on neurobiological aspects of the
disorder derived from pathological and laboratory studies of
affected individuals (4, 5). The identification of MECP2 muta-
tions, which cause a defect in synaptic maturation and mainte-
nance (6), as the etiology of most cases of RTT, represented
a major breakthrough for the development of new treatments.
The creation of experimental models of the disorder led to the
identification of downstream therapeutic strategies (4). Sub-
stantial reversal of mouse model neurologic phenotypes by ge-
netic manipulations, at different developmental stages (7, 8), has
supported the testing of several candidate drugs (4, 9). A par-
ticularly attractive candidate drug is recombinant human insulin-
like growth factor 1 (rhIGF-1) (IGF-1). IGF-1 is one of the most
potent activators of the AKT signaling pathway and may potentiate
the function of brain-derived neurotrophic factor, a key target of
MeCP2’s transcriptional regulation (10). There is also evidence that
MeCP2 regulates the expression of IGF-binding protein 3
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brains of RTT patients and Mecp2-null mice (11). Furthermore,
administration of IGF-1 restores dendritic spine dynamics in
Mecp2-deficient mice (12). The most compelling data supporting
IGF-1 as a treatment for RTT come from two studies demon-
strating that systemic administration of either full length IGF-1
or its active peptide fragment reverses, at least partially, many
RTT-relevant features in Mecp2-deficient mice (13, 14). Among
the latter are locomotor function impairment, breathing abnor-
malities, and heart rate irregularities. These improvements seem
to reflect IGF-1’s effect on defective synaptic maturation and
maintenance secondary to Mecp2 deficit (14).
Mecasermin, recombinant human IGF-1, is already Food and
Drug Administration-approved for the long-term treatment of
growth failure in children with severe primary IGF-I deficiency
(Laron syndrome) (15). We carried out a multiple ascending
dose (MAD) study followed by an open-label extension (OLE)
period with mecasermin in a group of 12 girls with MECP2
mutations, 9 of whom had RTT. Here, we report our findings on
safety, tolerability, pharmacokinetics (PK), and preliminary assess-
ments of efficacy. The latter include evaluations of neurobehavioral
measures, exploratory biomarkers, and their corresponding phar-
macodynamics (PD) data.
Results
Twelve girls with MECP2 mutations participated in the 4-wk
MAD; 10 of them continued and completed the subsequent
20-wk OLE. Fig. S1 illustrates the timeline of this phase 1 trial.
Participants’ demographic and baseline characteristics are shown
in Table 1. Nine subjects met full diagnostic criteria for RTT and
all continued in the OLE. The 4-wk MAD focused on obtaining
PK data, determining cerebrospinal fluid (CSF) penetration,
initial evaluations of safety and tolerability, and estimating fea-
sibility of automated cardiorespiratory measures as biomarkers
for treatment response. The OLE was designed to obtain addi-
tional information on safety, tolerability, and the aforemen-
tioned cardiorespiratory measures after chronic dosing, as well as
preliminary data on neurologic and behavioral parameters of
clinical relevance to RTT. These neurobehavioral evaluations
were based on questionnaires and assessments used in an on-
going multisite longitudinal study [the Rett Natural History study
(U54 HD061222)] and on two standardized measures of problem
behaviors. Data on safety, tolerability, and PK is reported for all
12 MECP2 mutation-positive subjects, whereas preliminary ef-
ficacy and PD data only for the 9 subjects with RTT.
During the MAD, mecasermin dosing was escalated over a
4-wk period, beginning with twice daily (BID) injections of 40
μg/kg the first week, 80 μg/kg the second week, and 120 μg/kg
during the third and fourth weeks, as depicted in Fig. S2. CSF
samples were obtained before drug administration and after com-
pleting the fourth week (Fig. S2). Fig. 1 illustrates levels of IGF-1
and IGFBP3, the main IGF-1-binding protein (10, 11), in serum
and CSF. There was a significant increase in IGF-1 but not IGFBP3
in both compartments at the end of the MAD. At the start of the
OLE, subjects went through an identical dose escalation, staying
on the maximum dose of 120 μg/kg for the remaining 17 wk of
treatment.
Serum IGF-1 concentrations were first analyzed by a non-
compartmental analysis (16) comparing different doses. A log-
linear terminal phase was observed after 4–6 h postdosing (Fig.
2A). The slopes of this decay allowed the estimation of terminal
elimination half-lives (t1/2,λ) and mean residence times in the
body (MRTb) as shown in Table S1. Maximal concentrations
(Cmax) and the times to reach them (tmax) were also documented.
The areas under the curve (AUCt; t, time of last observation) up
to the last observation lacked dose proportionality, suggesting
nonlinear kinetics (Fig. 2B). The starting dose of 40 μg/kg eli-
cited a mean AUCt = 2,050 ng·h/mL, while the area for twice
that dose increased by just 75%. When the starting dose was
tripled, the increment was nearly the same. Nonlinearity is also
supported by the early parts of the concentrations profiles, with
upward deviations after reaching maximum levels. We also
carried out a compartmental analysis using a two-compartment
model based on calculated Akaike and Bayesian information
criteria, as well as on the residuals analysis (16). A Michaelis–
Menten elimination kinetics (16) with first order absorption
and a distribution clearance parameterization provided the best
goodness of fit, compared with first order or mixed elimination
alternatives. The volume of distribution for the central com-
partment (V1/F) was estimated to be 7.71 ± 0.78 L (mean ± SE)
and for the peripheral compartment it was 33.5 ± 16 L. The other
parameters in the model were estimated for intercompartmental
clearance as 0.38 ± 0.048 L/h, for the maximum elimination rate
as 1.02 ± 0.4 μg·kg
−1·h
−1, and for the Michaelis–Menten constant
as 4.62 ± 3.7 ng/mL. Individual subjects’ noncompartmental
curves are depicted in Fig. S3 and Fig. S4 demonstrates the
appropriateness of the proposed models (i.e., predicted vs.
observed grouped data).
Based on direct compliance monitoring and serum levels, s.c.
injections were well tolerated and no incidences of hypoglycemia
or errors in dose administration were detected. During the
MAD, one serious adverse event occurred (respiratory distress)
and was determined to be unrelated to the study drug (10, 15).
During the MAD, only two adverse events (nausea and vomiting)
were considered as probably related to the study drug and pre-
ceded withdrawal from the OLE. A similar profile of safety and
Table 1. Subject demographics and characteristics at baseline
Age, y Diagnosis Stage MECP2 mutation Concomitant medications Breathing phenotype
3 Classic II R168X None None
7 MRD* n/a
† C1135_1142 del None None
7 MRD* n/a
† C1135_1142 del None None
2 Classic II C790_808 del Levetiracetam BH, HV, AE
5 Classic III Large del exon 3 and 4 None BH, HV
4 Classic III C1159_1273 del None AE
‡
8 Classic III R255X Lamotrigine, lorazepam, melatonin BH, AE
§
4 Classic III R255X None AE
8 Classic III T158M None BH, AE
§
3 MRD n/a
† R306C None None
10 Classic III Large del exon 1 and 2 Gabapentin, diastat BH, AE, cyanosis
§
8 Classic III P322L Levetiracetam BH, AE, cyanosis
§
AE, air expulsion; BH, breath holding; HV, hyperventilation.
*Subjects did not continue in OLE.
†Staging not applicable (n/a) to non-RTT.
‡Subject with mild apnea (apneic episodes >10 s and <5 apneas per hour).
§Subjects with moderate–severe apnea (apneic episodes >10 s and >5 apneas per hour).
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adverse events, was observed during the OLE. Although a high
proportion of the subjects had abnormal cholesterol levels at
baseline, these did not worsen during the trial. For details on ad-
verse events, see Table S2.
Using cardiorespiratory data obtained with a BioRadio device
(17), we calculated the apnea (18) and hyperventilation (19)
indices and compared the start and end of the MAD (pre- to
post-MAD), start and end of the OLE (pre- to post-OLE), and
beginning and end of the entire trial (pre-MAD to post-OLE).
We applied paired t tests, Wilcoxon signed rank tests, and
a random intercept (RI) model, illustrating time effects at each
time point (post-MAD, pre-OLE, and post-OLE compared with
pre-MAD). As illustrated in Table 2 (see “apnea index by time
point” entries), based on the RI model which accounts for
within-subjects correlation, the improvement in the apnea index
was significant at the end of the OLE in comparison with start of
the MAD. Improvements in the apnea index were comparable
when only the five subjects with clinically significant apnea
(apneic episodes >10 s), four of whom had moderate–severe
apnea, were included in the analyses (Table S3). Fig. S5 depicts
the trajectories of the apnea index for all subjects. In addition,
despite the small sample, we tested the effect of age as a cova-
riate in the RI model for all nine subjects with RTT. The effect
of age and its interaction with the respective time points was
positive and significant, namely the improvements in the apnea
index were more significant in older subjects. These patterns of
improvement were not observed for the hyperventilation index
(see “hyperventilation index by time point” entries in Table 2).
The specificity of the apnea index improvements are under-
scored when other respiratory parameters (20), typically not used
in the clinical context, are examined. Table S4 shows that during
the OLE, for instance, the percent epoch in slow respiratory rate
and the mean total respiratory cycle times (Ttot) in slow respi-
ration also decreased significantly but not the percent epoch in
rapid respiratory rate and the mean Ttot in rapid respiration.
Similar results were found in the MAD. There were also changes
in the cardiac parameters, namely a reduction in the percent
epoch in normal heart rate with a concurrent increase in the
percent epoch in rapid heart rate when the beginning and end of
the OLE were compared. Variance in heart rate also decreased,
although not significantly (Table S4). Similar to the breathing
parameters, changes in cardiac variables demonstrated the same
trend during the shorter MAD and the longer OLE. Preliminary
PD analyses indicate a positive response, namely a decrease in the
apnea index, over the course of treatment. Just in a few cases this
decrease leveled off or, in one case, seemed to revert at the end of
the MAD (Fig. S6 illustrates examples of different PD profiles).
During the OLE, preliminary efficacy data were gathered by
administering two RTT-oriented clinician assessments and two
standardized behavioral measures to the nine RTT subjects. We
focused on established instruments already reported in the lit-
erature (21–25), and did not include parent or clinician global
impression assessments, to decrease data subjectivity and allow
for future comparisons with other publications. Neurologic and
behavioral parameters were measured by two evaluations from
the Rett Natural History study (21), as well as the Rett Syn-
drome Behavioral Questionnaire (RSBQ) (22, 23) and the
Anxiety Depression and Mood Scale (ADAMS) (24, 25). We
performed exploratory comparisons between onset and end of
the OLE using t tests and the Wilcoxon signed rank test. Al-
though not significantly different, total scores showed a trend
toward improvement in all instruments. We then organized
the subscales of these measures into neurobehavioral domains
(e.g., motor, breathing/autonomic, problem behavior) and
subjected them to exploratory t tests comparing pre- to post-
OLE. We followed these hierarchical analyses by examining the
items in the same subscales. These analyses revealed significant or
trend-level changes in the breathing/autonomic and behavioral
domains. However, the direction of change in breathing and pe-
ripheral autonomic subscales were inconsistent. For instance,
breath-holding items in the RSBQ showed improvement whereas
those on the clinical assessment (CA) and motor–behavioral as-
sessment (MBA) worsened. Similar inconsistencies were present
for peripheral autonomic scales/items. Subscales and items rep-
resenting alertness, activity, anxious behaviors, or abnormal mood
demonstrated consistent improvements, whereas those recording
irritability, aggressiveness, disruptive/hyperactive behavior, com-
munication, and motor domains did not (Table 3 and Fig. S7).
Relative right-sided resting frontal (alpha band) EEG asym-
metry has been used in multiple studies as an index of anxiety
and depression (26), including pediatric populations (27). Left
(L) greater than right (R) alpha power is typically interpreted as
more positive vs. negative (less anxious vs. more anxious) be-
havior, whereas R > L is viewed as the reverse. As depicted in
Fig. 3, six subjects evaluated during the OLE with EEG dem-
onstrated R > L asymmetry (i.e., more anxious). Although the
degree of asymmetry was variable, five of the six showed a de-
crease in the asymmetry index and in three it was reversed. A
paired-samples t test revealed that this group trend toward L > R
asymmetry (i.e., reduction in anxiety) was significant. Moreover,
IGF-1 (ɳg/mL) IGFBP-3 (ɳg/mL)
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Fig. 1. IGF-1 and IGFBP-3 levels in CSF and serum pre- and post-MAD. The
Mean and SE of IGF-1 and IGFBP-3 in serum and CSF are shown (P values
based on Student’s t test). CSF and serum samples were obtained before IGF-1
administration on day 1 and 1–2 h after dose on day 29 (n = 12). Levels of IGF-1
in serum and CSF more than doubled, indicating IGF-1 reaches the CNS com-
partment. IGFBP3, the main IGF-1-binding protein, did not significantly in-
crease in serum or CSF.
AB
Fig. 2. (A) Serum IGF-1 concentrations show a log-linear terminal phase
4–6 h after dosing. Serum IGF-1 concentrations were analyzed by a noncom-
partmental analysis comparing escalating doses at days 1, 8, 15, and 29. A log-
linear terminal phase was observed after 4–6 h postdosing. The slopes of decay
allowed the estimation of t1/2,λ and MRTb are described in Table S1.( B)A s
shown, the mean and SE of the AUCt of IGF-1 suggests nonlinear kinetics.
The AUCt up to the last observation lacked dose proportionality, suggesting
a nonlinear kinetics. The lowest dose of 40 μg/kg BID dose elicited a mean
AUCt = 2,050 ng·h/mL whereas the area for twice that dose (80 μg/kg BID)
incremented just about 75%. When the lowest dose was tripled (120 μg/kg
BID) at day 15, the increment was nearly the same. The Mean and SE of the
AUCt in serum and CSF are shown.
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with improvements in measures of mood abnormalities and, to
lesser extent in measures of breathing abnormalities and anxiety
(Table S5). Analyses of cardiorespiratory and neurobehavioral
parameters excluding the two individuals in Hagberg stage II
(i.e., end of regression period) did not yield significantly different
results from those including all nine RTT subjects.
Discussion
Our findings indicate that IGF-1 is safe for use in girls with MECP2
mutations, including those meeting diagnostic criteria for RTT. We
found that mecasermin reaches the CNS and that its kinetics are
complex, as expected from a protein that is cleaved and binds its
receptor and interacting proteins (10, 11, 28, 29). Our preliminary
efficacy analyses suggest that, when administered over several
weeks, mecasermin improved certain aspects of the RTT pheno-
type, most notably, abnormal behaviors (i.e., anxiety) and breathing
abnormalities (i.e., apnea). Changes in breathing abnormalities
were better characterized using automated measurements of
cardiorespiratory function. The evaluation of potential biomarkers
also successfully delineated behavioral abnormalities with right-
sided frontal alpha band EEG asymmetry, an index of anxiety
and depression, showing a trend toward reversal in most RTT
subjects exhibiting the phenomenon. Overall, the findings of this
phase 1 trial are in agreement with preclinical data suggesting
IGF-1 is a safe and beneficial treatment of RTT (13, 14).
As recently reported by Pini et al. (30), mecasermin adminis-
tration is relatively safe and well tolerated. In our own phase 1
study, several expected adverse events, such as increased tonsil
size and related snoring, were observed but were relatively mild
and nonprogressive and did not lead to withdrawal from the trial.
Most subjects had elevated cholesterol; however, this preceded
IGF-1 administration and did not worsen with the drug. There-
fore, concerns about metabolic syndrome raised by a recent animal
study (31) were not supported by our trial. The most common
adverse event, early signs of puberty, may be significant as some
reports have shown accelerated puberty (i.e., early adrenarche)
in RTT (32, 33). Nonetheless, because hormonal levels were
within normal ranges throughout the study, this issue deserves
further investigation. In summary, at the doses used in this
(240 μg·kg
−1·d
−1) and the previously published (200 μg·kg
−1·d
−1)
trial (30), mecasermin is a safe treatment.
Our data indicate that mecasermin administration increases
IGF-1 levels in the CNS (10); therefore, our data on efficacy and
some of the adverse events could be attributed to the presence
of IGF-1 in the brain. The IGF-1 increase in CSF depicted in
Fig. 1 is comparable to the one in positive responders to flu-
oxetine (34) or adrenocorticotropic hormone (35). The levels of
IGFBP3, the main IGF-1-binding protein (10), were unaffected
by the increase in IGF-1. This suggests that increased IGFBP3 as
a mechanism underlying RTT pathophysiology (11) is not cor-
rected by mecasermin, at least at the dosages used in this trial.
Despite their normal serum levels, our subjects exhibited
a nonlinear PK profile of IGF-1 (36). This is not unexpected for
a protein with complex regulation, mechanism of action, and
pleiotropic effects (10, 37, 38). Recent data demonstrating acti-
vation of different signaling pathway by full length IGF-1 and its
active breakdown product (29) highlights this issue. The dose
used in this study, 240 μg·kg
−1·d
−1, was selected based on the
investigational medicinal product’s current approved labeling
and its efficacy in preclinical studies (13, 14). Several PK
parameters in our study (e.g., Cmax, t1/2, tmax) and their changes
with increasing doses of mecasermin (Cmax) are comparable to
those found in healthy volunteers and children with primary
IGF-1 deficiency (39). As we observed, chronic treatment PK
studies have suggested a plateau effect for doses between 160–
240 μg·kg
−1·d
−1, probably reflecting saturation of IGFBP3 (38).
The nonlinear PK kinetics, greater volume distribution in the
peripheral than the central compartment, and lack of change in
IGFBP3 in serum and CSF suggest that serum levels of IGF-1 for
may not be the best basis for dosing and that higher or chronic
dosing in RTT may not necessarily result in higher exposures or
a sustained exposure–response relationship. This leads to careful
consideration of dosing for future studies where acute intermittent
pulsesofmecaserminmaybemoreeffectivethanchronicdosing.The
mouse model may be useful in exploring optimum dosing regimens.
Our study confirmed the feasibility of automated cardiore-
spiratory measurements as biomarkers of treatment response
(40). It also indicates that these breathing evaluations may be
more reliable and valid than clinical instruments because parent
questionnaire data were in disagreement with clinicians’ obser-
vations. Whether these discrepancies reflect different lengths
of observations (i.e., days to weeks for parents vs. minutes for
clinicians) is unclear. Regardless, the measurements obtained
during both the MAD and OLE demonstrate a consistent trend
toward improved breathing. Other parameters obtained during
the automated assessments further emphasize IGF-1’s selective
effect on slow breathing, initially shown in the RTT mouse
model (14). Although the lack of improvement in hyperventila-
tion may have been influenced by technical issues (e.g., move-
ment artifact), the selective effect on apnea is still desirable as it
is perceived as more concerning clinically (41). Our preliminary
dose–response analyses suggest that reduction in the apnea index
is the result of IGF-1 administration; nonetheless, the revert-
ing trend observed in a few subjects toward the end of the MAD
(Fig. S6) may reflect the aforementioned saturation kinetics of
IGF-1. Additional PD analyses, focusing on exposure–response
relationships, need to be conducted to clarify this issue. The
effects of IGF-1 on cardiac function were challenging to in-
terpret. Although decreased heart rate variability may be seen as
positive, its association with a trend toward higher heart rate may
be considered a potential side effect. However, heart rate values
remained within the wide normal range (42). Although the possible
effect of mecasermin on heart rate warrants further in-
vestigation, our findings are in line with the partial correction
of bradycardia in the Mecp2-null mouse (14).
Our preliminary efficacy evaluations on neurobehavioral
parameters provided a mixed picture. Whereas some measures
indicated improvements, others worsened. This was particularly
the case for abnormalities in breathing and peripheral autonomic
function. A similar inconsistent pattern was found for externaliz-
ing problem behaviors, such as disruptive and irritable behaviors.
Two other important domains—communication and motor func-
tion, including abnormal movements—did not show a change.
Table 2. Summary of breathing indices for all RTT subjects by time point (n =9 )
Breathing indices Pre-MAD Post-MAD Pre-OLE Post-OLE Pre-MAD to Post-OLE
Apnea index (mean ± SE) 10.11 ± 19.34 5.11 ± 9.68 4.67 ± 6.81 3.00 ± 5.72 −7.12 ± 4.58
Student’s tP – ––– 0.159
Wilcoxon signed rank P – ––– 0.094
RI model P – ––– 0.018
Hyperventilation index (mean ± SE) 3.55 ± 6.71 3.00 ± 6.59 6.44 ± 16.86 3.66 ± 8.97 0.12 ± 0.93
Student’s tP – ––– 0.908
Wilcoxon signed rank P – ––– 0.875
RI model P – ––– 0.963
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cluding fear and avoidance) and mood abnormalities (e.g., in-
appropriate laughter) showed modest although consistent
improvements among measures that included two standardized
behavioral scales (i.e., RSBQ, ADAMS). These findings were
supported by the partial or complete reversal of right-sided
alpha band frontal EEG asymmetry in five of the six subjects
presenting with this phenomenon, which correlated with improved
scores on mood abnormalities and anxiety. Because EEG frontal
asymmetry has been linked to depression and particularly to anxiety
in children (26, 27), its use in RTT and other neurodevelopmental
disorders may serve as an effective tool for assessing drug efficacy.
O u rf i n d i n g so fI G F - 1 ’s effect on anxiety are in agreement with
data from studies in the animal model (14).
The data presented here suggest that administration of IGF-1
is a promising treatment for RTT. Its safety and tolerability
profiles are acceptable considering the severity of the targeted
symptoms. However, the potential long-term use of mecasermin
should be weighed against its potential effects on puberty, which
is already accelerated in RTT (32, 33). The complex pharma-
cology of IGF-1 makes the determination of an optimal dosage
difficult; the positive effects reported here indicate that long-
term treatment may be necessary, which is not surprising con-
sidering IGF-1’s likely effects on synaptic maturation and
maintenance (6, 13, 14). The effect of IGF-1 was mild and
selective, influencing certain cardiorespiratory and neuro-
behavioral features of RTT. Although this may seem unexpected
given the context of IGF-1’s extensive efficacy in the mouse
model (14), it is not surprising compared with trial results in
other neurodevelopmental disorders. In fragile X syndrome,
mGluR5 antagonists (43) and GABA-B agonists (44) had simi-
larly selective effects in human trials, but were preceded by
a more generalized reversal of the phenotype in preclinical
studies (45, 46). Interaction between the primary genetic defect
and the individual’s own genetic background is one of several
mechanisms that may contribute to these discrepancies.
It is important to recognize the limitations of the present study.
The first limitation is the relatively small sample and age range
considering the dynamics of RTT. Nine of the subjects met RTT
diagnostic criteria and only seven were at a stable period (Hagberg
stage III) (2). Nevertheless, analyses excluding the two individ-
uals in stage II did not yield different results. Although the in-
clusion of twins with MECP2-related disorder (MRD) allowed
for the examination of safety and PK in individuals with other
MRDs, it also decreased the variability of the sample. This study
was designed to assess CNS penetration and PK profile of IGF-1,
and to test the feasibility of automated cardiorespiratory mea-
sures; as such, RTT subjects were not selected on the basis of
breathing abnormalities or specific profiles of neurobehavioral
impairment. This increased the heterogeneity of the already
small sample, leading to diminished statistical power. Analyses of
the clinically oriented measures used discovery type statistics
without correcting for multiple comparisons and emphasizing the
consistency of the body of data rather than specific parameters.
On the other hand, comparisons between onset and end of the
OLE, without considering intermediate time points may have
overlooked transient positive effects of IGF-1. Although mea-
sures from the Rett Natural History study (21) were selected
because of their relevance, these instruments have not been
validated as outcome measures, and discrepancies between the
parent questionnaire and clinician assessment need to be further
examined. Also, the ADAMS (24, 25), has not been validated in
RTT. Increased care and placebo effect could have also influ-
enced our neurobehavioral findings. Nonetheless, the use of
automated measures such as the BioRadio for cardiorespiratory
function (17) or EEG asymmetry profiles for anxiety and mood
(26, 27) strengthened clinician- and parent-reported data and
support future exploration of biomarkers. Additional bio-
marker data—namely the Q sensor (47) for recording motion
and hand stereotypies and visual evoked potentials for examining
cortical function (48)—was collected as part of this trial and
needs to be analyzed and reported in future publications.
Methods
Sample. Characteristics of our cohort are shown in Table 1 and SI Methods.
The study was approved by the Institutional Review Board of Boston
Children’s Hospital and informed consent was obtained from the parent of
each participant. Further information is provided in SI Methods.
Study Design and Safety Measures. Unblinded phase 1 study designed to
establish PK profile (4-wk MAD) and long-term safety and tolerability (20-wk
OLE) of IGF-1 in girls with RTT (Fig. S1). Subjects received twice daily (BID) s.c.
injections at 40 μg/kg (week 1), 80 μg/kg (week 2), and 120 μg/kg (weeks 3, 4,
OLE) (Fig. S2). Safety was assessed by evaluations listed in Table S6. Detailed
information is provided in SI Methods.
PK and PD Analyses. Sera were obtained at different daily time points during
the MAD, and at each visit during the OLE, while CSF only at the beginning
and end of the MAD (Fig. S2). Methodologies for IGF-1 and IGFBP3 measure-
ments, and PK and pharmacodynamics analyses, are detailed in SI Methods.
Automated Cardiorespiratory Measures. Time synchronized chest respiratory
inductive plethysmography, three lead electrocardiography, and video record-
ings are detailed in SI Methods.
Table 3. Neurobehavioral measures between V1 and V5
Measure V1 mean V5 mean
Mean
difference
Mean
difference SE Student’s tP
Wilcoxon signed
rank P
Behavioral subtotal (MBA) 24.00 19.88 −4.11 1.11 0.006 0.016
Passive/unengaged (CA) 0.33 0.00 −0.33 0.17 0.081 0.250
Intermittent laughter (CA) 0.33 0.00 −0.33 0.17 0.081 0.250
Fear/anxiety subtotal (RSBQ) 3.55 2.77 −0.79 0.66 0.274 0.281
Spells of laughter at night (RSBQ) 0.77 0.44 −0.33 0.17 0.081 0.250
Social avoidance subtotal (ADAMS) 4.55 3.11 −1.44 0.84 0.122 0.109
V1, visit 1 of OLE; V5, visit 5 of OLE.
Average 6 5 4 3 2 1
Pre-OLE
Post-OLE
8
6
4
2
0
-2
-4
-6
-8
Subjects
Fig. 3. Right-sided frontal alpha band EEG asymmetry shows a trend toward
reversal. Greater relative L vs. R alpha activity has been interpreted as greater
positive effect/less anxiety and greater R vs. L the opposite. Six subjects eval-
uated before the OLE demonstrated R > L asymmetry. Although the degree of
asymmetry was variable after OLE, five of the six showed a decrease in the
asymmetry index and in three there was a reversal. A paired-samples t test
revealed significant group differences pre- and post-OLE.
4600 | www.pnas.org/cgi/doi/10.1073/pnas.1311141111 Khwaja et al.Neurobehavioral Assessments. Table S4 lists the multiple measures of neuro-
logic and other functions obtained during the OLE. Additional information is
presented SI Methods.
EEG Recordings. EEG recording, spectral power analysis, and frontal asym-
metry scores were performed as reported (49–51) and detailed in
SI Methods.
Statistical Analyses. Standard descriptive and comparative statistics were
employed. Specific tests are specified in Results and SI Methods.
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